Evidence map›Paper›PMID 41224272›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Contrasting Outcomes in Two Cases of Anti-contactin-associated Protein-like 2 Autoimmune Encephalitis.

Kazuki Yamada, Hiroaki Yaguchi, Shuntaro Nakamura, Kazuhiro Horiuchi, Shintaro Fujii, Taichi Nomura, Akihiko Kudo, Kenta Tasaki, Makoto Hara, Hideto Nakajima and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kazuki YamadaDepartment of Neurology, Hakodate Municipal Hospital, Japan.
Hiroaki YaguchiDepartment of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan.
Shuntaro NakamuraDepartment of Neurology, Hakodate Municipal Hospital, Japan.
Kazuhiro HoriuchiDepartment of Neurology, Hakodate Municipal Hospital, Japan.
Shintaro FujiiDepartment of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan.
Taichi NomuraDepartment of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan.
Akihiko KudoDepartment of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan.
Kenta TasakiDivision of Neurology, Department of Internal Medicine, Nihon University School of Medicine, Japan.
Makoto HaraDivision of Neurology, Department of Internal Medicine, Nihon University School of Medicine, Japan.
Hideto NakajimaDivision of Neurology, Department of Internal Medicine, Nihon University School of Medicine, Japan.
Ichiro YabeDepartment of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report two cases of anti-contactin-associated protein-like 2 (CASPR2) autoimmune encephalitis in men in their 70s. Both patients presented with seizures and psychiatric symptoms that required sedation and mechanical ventilation. The treatment included high-dose intravenous methylprednisolone, plasma exchange, and rituximab. One patient fully recovered (modified Rankin Scale [mRS] score 0), whereas the other remained severely disabled (mRS score 5). This difference in outcome may be attributed to the time from symptom onset to treatment initiation. These cases highlight the importance of an early diagnosis and timely immunotherapy for anti-CASPR2 autoimmune encephalitis.

Indexed as

EncephalitisHashimoto DiseaseMembrane ProteinsNerve Tissue ProteinsAgedAutoantibodiesHumansMaleMethylprednisolonePlasma ExchangeRituximabTreatment OutcomeAutoantibodiesCNTNAP2 protein, humanMembrane ProteinsMethylprednisoloneNerve Tissue ProteinsRituximabanti-CASPR2 autoimmune encephalitisautoimmune encephalitiscontactin-associated protein-like 2 (CASPR2)

Identifiers

PMID41224272
PMCPMC13423780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.